The power of fat and its adipose-derived stromal cells: emerging concepts for fibrotic scar treatment

Maroesjka Spiekman1, Joris A. van Dongen1,2, Joep C. Willemsen1,2, Delia L. Hoppe3, Berend van der Lei2 and Martin C. Harmsen1*

1Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands
2Department of Plastic Surgery, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
3Department of Plastic and Reconstructive Microsurgery/Handsurgery, Charité University Medicine, Ernst Von Bergmann Clinic, Potsdam, Germany

Abstract

Lipofilling or lipografting is a novel and promising treatment method for reduction or prevention of dermal scars after injury. Ample anecdotal evidence from case reports supports the scar-reducing properties of adipose tissue grafts. However, only a few properly controlled and designed clinical trials have been conducted thus far on this topic. Also, the underlying mechanism by which lipofilling improves scar aspect and reduces neuropathic scar pain remains largely undiscovered. Adipose-derived stromal or stem cells (ADSC) are often described to be responsible for this therapeutic effect of lipofilling. We review the recent literature and discuss anticipated mechanisms that govern anti-scarring capacity of adipose tissue and its ADSC. Both clinical and animal studies clearly demonstrated that lipofilling and ADSC influence processes associated with wound healing, including extracellular matrix remodelling, angiogenesis and modulation of inflammation in dermal scars. However, randomized clinical trials, providing sufficient level of evidence for lipofilling and/or ADSC as an anti-scarring treatment, are lacking yet warranted in the near future. © 2017 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley & Sons Ltd

Received 8 February 2016; Revised 16 March 2016; Accepted 14 April 2016

Keywords lipofilling; adipose tissue; adipose-derived stromal/stem cells; stromal vascular fraction; dermal scar; scar treatment

1. Development of lipofilling procedures

Transfer of adipose tissue, also known as fat grafting, lipografting or lipofilling, is recognized as a promising and novel technique for correction of volume deficiency, skin rejuvenation and as treatment for scars. This is strongly supported by evidence-based clinical trials as well as fundamental studies in animals and in vitro. The first case of lipofilling in literature dates from 1893, when Gustav Neuber described the first free fat transfer for a scar that had left a young man with a soft tissue defect of the face (Neuber, 1893).

As soon as liposuction was further developed in the mid 1980s, also interest developed of re-using the liposuaspirated subcutaneous adipose tissue. Liposuction pioneers such as Illouz and co-workers (Illouz, 1983) developed the first clinical applications and methods for lipofilling to restore or gain volume. The real breakthrough in lipofilling came with fat harvesting, subsequent processing and subcutaneous administration as described by Coleman (2002), which allowed better survival of the lipograft. Centrifugation was the first successful attempt to improve fat graft survival by removing oil, fluid and dead cells from the harvested fat tissue. This method also inspired clinical trials to assess volumetric augmentation of the breast and buttocks (Cardenas-Camarena et al., 2011; Khouri et al., 2012).

Initially, introduced by Coleman in the early 1990s, the use of small liposuction and lipofilling cannulas also opened the door for lipofilling of the face and hands for both reconstructive and aesthetic purposes. Especially in these applications with rather superficial lipofilling, effects described as ‘more than volume alone’ were often observed (Coleman, 2002, 2006). This included an improved appearance and quality of the skin, and has subsequently been described in many case reports. Yet a mechanistic underpinning was still lacking. These clinical observations initiated a wide range of clinical applications for lipofilling other than just volume adjustment (Rigotti et al., 2007). This novel idea to use lipofilling for treatment of (the consequences of) tissue damage has led to the use of lipofilling to treat burn scars (Klinger et al., 2008) and even to alleviate scar-associated pain as occurring for example after mastectomy (Caviggioli et al., 2011).

In 2001, Zuk and colleagues (Zuk et al., 2001) demonstrated that adipose tissue had a source of endogenous mesenchymal stem cells (MSC), which were named adipose-derived stem or stromal cells (ADSC). This discovery significantly advanced the use of lipofilling as a regenerative therapy, as it had been shown that at least one of the components of adipose tissue had therapeutic

*Correspondence to: Martin C. Harmsen, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen, Hanzeplein 1 (EA11), 9713 EZ Groningen, the Netherlands. E-mail: m.c.harmsen@umcg.nl

© 2017 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley & Sons Ltd

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
potential. Since then, many of the beneficial effects observed after lipofilling have been attributed to ADSC.

In this review the authors, both clinicians and biologist, try to bridge the gap between both worlds, provide a review of recent literature and summarize the possible mechanism behind the anti-scarring effect of adipose tissue and its ADSC.

2. Lipofilling on a cellular level

Liposuction simply implicates the harvest of adipose tissue under negative pressure with small-bore suction cannulas. By this, the architecture of the fat tissue is disrupted and small lumps of adipose tissue are harvested and collected in a sterile environment (bag or collector), which can then be used for lipofilling subsequently. Inevitably, some degree of hypoxia occurs around the grafting of the liposapirate. In the recipient, the integration of the graft requires extensive (re)vascularization, which is primed by the occurring hypoxia as well as by the pre-existing microvasculature in the graft. Too large ‘lumps’ of lipograft obviously develop necrotic cores due to diffusion insufficiency, as a result of which the graft ‘take’ may be reduced (Dong et al., 2013; Eto et al., 2012; Kato et al., 2014). Adipocytes are sensitive to hypoxia and as a consequence prone to apoptosis (Eto et al., 2012; Kato et al., 2014; Suga et al., 2010). Depending on the technical and time that is required for harvesting and lipofilling (Fisher et al., 2013; Pu et al., 2008), 40–90% of the injected lipograft volume will remain (Hivernaud et al., 2015), while the rest is resorbed within months after grafting. Oily cysts may remain in the grafted area as a consequence of this fat necrosis. To improve fat graft survival, different processing techniques are used (e.g. centrifugation, decantation, gauze-towel technique). In a systematic review, these techniques are compared for viability of the fat graft as a whole (Tuin et al., 2016) in terms of number of viable cells and in terms of graft volume survival in human and animal models. For fat graft survival, the gauze-towel processing technique is found to be superior to centrifugation or decantation. However, if the focus lies on the number of ADSC in adipose grafts, centrifugation improves the number of ADSC that can be isolated, compared with a non-centrifuged fat (Ibatici et al., 2014). Thus, depending on the goal of lipofilling, different fat-processing techniques need to be considered carefully.

Adipose tissue, the energy storehouse of the human body, consists of a parenchymal mass of adipocytes that is structurally supported by connective tissue and perfused by blood vessels. All non-adipocyte tissue is called stroma or stromal tissue. Adipocytes are the main volumetric component of adipose tissue, although they only comprise up to 20% of all cells (Eto et al., 2009). Adipocytes consist of a thin layer of cytoplasm with an eccentric nucleus, while most of the volume is made up by the large central vacuole in which triglycerides predominantly are stored (Carmen and Victor, 2006). During development, adipose tissue is derived from the mesodermal germ layer. The MSC that reside in the mesoderm differentiate into adipocytes to form adipose tissue. However, after the embryogenic formation of adipose tissue, some of the MSC or stromal cells remain. In the adult situation, these MSC are the previously mentioned ADSC. In the adipose tissue, ADSC reside around the vasculature (Crisan et al., 2008; Lin et al., 2008; Tang et al., 2008; Traktuev et al., 2008). Furthermore, ADSC retain the ability to differentiate into adipocytes, thus functioning as a source to regenerate adipose tissue (Cawthorn et al., 2012).

3. Lipofilling as a method to treat scars

As stated above, lipofilling is beneficial for skin and scar treatment. In recent years, a limited number of retrospective and prospective studies supported previous anecdotal clinical observations (Table 1a).

3.1. Clinical studies

The clinical efficacy of lipofilling in scar areas is determined by improvement of the appearance of a scar, such as size, thickness, stiffness, discoloration of the scar. In the case of painful scars, this effect can also be measured by a decrease in pain. In the first subsection of this summary of clinical studies, the focus lies on the ability of lipografts to improve several of the above-mentioned appearances of scars, whereas in the second subsection focus lies on the ability to reduce pain.

3.1.1. Scar appearance

Macroscopically, scars are characterized by a different appearance to the surrounding skin: discoloration, stiffness and roughness are features of scarring. In clinical studies, different outcome measures are used to quantify the degree of scarring on a macroscopic level. The first methods often used to assess scar severity are patient- or observer-rated grading scales, in which several aspects of scarring (e.g. colour, stiffness, thickness, irregularity) are rated. A second method is to use measuring devices for skin elasticity or dermal pigmentation.

The efficacy of lipofilling to improve scar appearance has been investigated in 16 case reports or clinical trials (Balkin et al., 2014; Bollero et al., 2014; Bruno et al., 2013; Coleman, 2006; Guisantes et al., 2012; Klinger et al., 2008; Maione et al., 2014a; Mazzola et al., 2013; Pallua et al., 2014; Phulpin et al., 2009; Ribuffo et al., 2013; Sardesai and Moore, 2007; Wang et al., 2013; Zellner et al., 2015; Table 1a). In 10 studies of these publications, comprising of a total of 156 patients, complications were recorded: in nine of these 10 studies no complications were recorded, whereas in one study with 12 patients there was a case of cellulitis reported as a complication. Hence, it seems that risks of lipofilling in scar areas are rather low. All 14 case reports or clinical
Table 1a. Clinical studies on lipofilling to improve scar appearance

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study type</th>
<th>Study population</th>
<th>Intervention</th>
<th>Follow-up</th>
<th>Results</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balkin et al. (2014)</td>
<td>Retrospective, controlled</td>
<td>Patients with cleft lip repair (n = 30, 37 sides). Immediately treated.</td>
<td>Intervention: subcutaneous, intra-muscular and periosteal lipofilling (n = 20). Control: no lipofilling treatment (n = 10).</td>
<td>Photographic analysis by 3 independent observers using a visual 5-grade scale (mean follow-up of 24.7 months).</td>
<td>Less cleft lip related deformity in overall facial, upper lip, nose and midface appearance in treated group.*</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Bollero et al. (2014)</td>
<td>Prospective, non-controlled, non-blinded, non-randomized</td>
<td>Patients with scars after trauma (n = 19).</td>
<td>Intervention: subcutaneous, intra-muscular and periosteal lipofilling (28 interventions)</td>
<td>Visual evaluation of photographs (pre-operative, 1 month and 3 months post-operative).</td>
<td>Among 28 interventions, 24 showed visual improvement in skin quality. 1 case showed improvement initially, but not after 3 months.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Bruno et al. (2013)</td>
<td>Prospective, controlled, non-blinded, non-randomized</td>
<td>Patients with burn wound scars (n = 93 scars). Mean scar age of 2.3 years.</td>
<td>Intervention: intra- and subcutaneous lipofilling (n = 93). Control: saline injection (n = 93).</td>
<td>Immunohistochemical analysis of scar biopsies, subjective evaluation using a questionnaire, photographic analysis by independent observers using the VSS (pre-operative, 3 months and 6 months post-operative).</td>
<td>Visual improvement in skin quality. 1 case showed improvement initially, but not after 3 months.</td>
<td>Not mentioned</td>
</tr>
<tr>
<td>Byrne et al. (2016)</td>
<td>Retrospective, non-controlled</td>
<td>Patients with burn wounds scars of hand (n = 13). Mean scar age of 2.3 years.</td>
<td>Intervention: subdermal lipofilling</td>
<td>Aesthetic, functional and satisfaction scores were measured using a TAM (Goniometer), GIM (Dynamometer), DASH, MHQ and POSAS (measurement at 3 years and 3 months post-operatively).</td>
<td>The mobility improved*, but there was no grip strength and DASH improvement. A trend towards significant improvement in POSAS scores was noticed. A significant improvement in the POSAS scores was visible, except the scores for pain and itch.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Guisantes et al. (2012)</td>
<td>Case-report</td>
<td>Patients with retractile and dystrophic scars (n = 8).</td>
<td>Intervention: intrascar lipofilling depending on treated area (11 interventions)</td>
<td>Photographic analysis by 2 independent observers using a visual 4-grade scale (mean follow-up of 18 months).</td>
<td>Improvement in skin quality, 5 cases obtained a score of 4, and 3 cases obtained a score of 3.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Klinger et al. (2008)</td>
<td>Case-report</td>
<td>Patients with scars as a result of hemifacial 2nd and 3rd degree burns (n = 3). Scar age of 2, 3 and 13 years.</td>
<td>Intervention: dermal-epidermal junction lipofilling (2 interventions per patient)</td>
<td>Histological evaluation of scar biopsies and MRS (pre-operative, 13 months post-operative during operation 2, 3 months post-operative).</td>
<td>Histological improvement: patterns of new collagen deposition and more dermal hyperplasia and neoangiogenesis. Presence of annexial structures is nearly normal. MRS revealed similar signal enhancement of soft tissue between affected and unaffected facial sides.</td>
<td>Not mentioned</td>
</tr>
<tr>
<td>Maione et al. (2014a)</td>
<td>Prospective, controlled, non-blinded, non-randomized</td>
<td>Patients with short-limb deformity syndrome presented</td>
<td>Intervention: saline and durometer measurements to measure skin hardness after treatment*.</td>
<td>Reduction of scar hardness after treatment*, while no</td>
<td></td>
<td>Not mentioned</td>
</tr>
</tbody>
</table>
### Table 1a. (Continued)

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study type</th>
<th>Study population</th>
<th>Intervention</th>
<th>Follow-up</th>
<th>Results</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mazzola et al. (2013)</td>
<td>Retrospective, non-controlled</td>
<td>Patients who underwent mastectomy followed by secondary intention resulting in a retracting scar (n = 11). Scar age of 4-10 years.</td>
<td>Intervention: lipolifting in the plane between skin and subcutaneous tissue (2 interventions, interval of 6-12 months).</td>
<td>Evaluation of patient satisfaction (mean follow-up of 21.3 months).</td>
<td>Patients described functional and aesthetical improvement and were all satisfied. 2 cases with severe retraction needed 1 additional lipolifting procedure.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Pallua et al. (2014)</td>
<td>Prospective, non-controlled, non-blinded, non-randomized</td>
<td>Patients with facial scars of different causes (n = 35).</td>
<td>Intervention: subcutaneous lipolifting</td>
<td>A POSAS, tissue oxygen saturation, haemoglobin levels and microcirculation (Doppler spectrometry) measurements performed (pre-operative, 1 month, 3 months, 6 months and 12 months follow-up).</td>
<td>Improvement in overall POSAS scores, both patient score as observer score.** Only 12 months scores mentioned. Early post-operative measurements revealed increased haemoglobin levels and reduced microcirculation, but both normalized after 7-90 days.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Phulpin et al. (2009)</td>
<td>Retrospective, non-controlled</td>
<td>Patients with aesthetic subcutaneous or submucous head and neck reconstruction after radiotherapy (n = 11).</td>
<td>Intervention: deep and superficial subcutaneous lipolifting.</td>
<td>Aesthetic and functional scores were measured using a 5-grade scale (mean follow-up of 39.9 months).</td>
<td>Skin scoring tests revealed more softness, more pliability and improvement of skin quality of the irradiated skin. No scores mentioned.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Ribuffs et al. (2013)</td>
<td>Retrospective, controlled</td>
<td>Patients underwent MRM and IIBR + PMRT (n = 32). Lipolifting performed 6 weeks after PMRT.</td>
<td>Intervention: deep and superficial subcutaneous lipolifting (n = 16).</td>
<td>Capsular contracture was measured using Bakers’ classification. Patients’ satisfaction was evaluated using a 3-grade scale. (Mean follow-up of 18 months).</td>
<td>No complications reported</td>
<td></td>
</tr>
<tr>
<td>Sardesai et al. (2007)</td>
<td>Prospective, non-controlled, non-blinded, non-randomized</td>
<td>Patients with various scar types (n = 14). Scar age of &gt; 1 year, 8.5 years on average.</td>
<td>Intervention: subcutaneous lipolifting</td>
<td>Dermal elasticity (Cutometer), vascularity and pigmentation (Derma-Spectrometer) measured. Patients’ perception (POSAS and VSS) and observers’ perceptions (POAS and VSS) evaluated (pre-operative and 12-16 months post-operative).</td>
<td>Increase of dermal elasticity** and no difference in vasculation and pigmentation. Decrease of scar stiffness and thickness in patients’ perception.** Less relief and pliability in observers’ perception using a POSAS, pliability decrease was confirmed using a VSS. **No difference in vasculation and pigmentation (POAS and VSS).</td>
<td>Not mentioned</td>
</tr>
<tr>
<td>Wang et al. (2013)</td>
<td>Retrospective, non-controlled</td>
<td>Patients with bilateral gluteal concave deformities associated with intragluteal injections (n = 12).</td>
<td>Intervention: deep, intermediate and superficial layer lipolifting of the gluteal</td>
<td>Effect of fat grafting on the skin was evaluated by severity of irregularity, quality of skin patterns and visual impact. Overall 9 cases scored 4-5 and 3 cases scored 3 on the satisfaction scale after treatment. Improvement in</td>
<td>1 case with cellulitis in the feet and calves</td>
<td></td>
</tr>
</tbody>
</table>
Table 1a. (Continued)

<table>
<thead>
<tr>
<th>Study type</th>
<th>Intervention</th>
<th>Study population</th>
<th>Follow-up</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retrospective, controlled</td>
<td>Patients with cleft lip repair surgery treated with lipofilling</td>
<td>$n = 35$ (52 sides), immediately post-operative</td>
<td>1 month</td>
<td>No pre-operative scores in overall facial, upper lip, nose and midface appearance ($&lt; 6$ months).* Photographic analysis by independent observers using a visual 5-grade scale (mean follow-up of 266 days). No significant improvement in overall lip appearance ($&lt; 6$ months) and overall nose area ($&lt; 6$ months).</td>
</tr>
<tr>
<td>Retrospective, controlled</td>
<td>Patients with cleft lip repair surgery treated with lipofilling</td>
<td>$n = 19$</td>
<td>6 months</td>
<td>Improvement in cleft lip-related deformity ($&lt; 6$ months).</td>
</tr>
<tr>
<td>Retrospective, controlled</td>
<td>Patients with cleft lip repair surgery treated with lipofilling</td>
<td>$n = 35$, 44 sides</td>
<td>Immediate post-operative</td>
<td>No improvement in skin texture was observed in all patients. No mention of wound healing complications.</td>
</tr>
</tbody>
</table>

Significant improvement in skin pliability, and all but one parameter of the patient and observer scar assessment scale improved. Thus, lipofilling apparently improves the appearance of existing scars.
3.1.2. Pain reduction

Efficacy of lipofilling as a means for pain reduction was investigated in six case reports or studies (Caviggioli et al., 2011; Huang et al., 2015a; Klinger et al., 2013; Maione et al., 2014b; Panettiere et al., 2009; Rigotti et al., 2007; Ulrich et al., 2012; Table 1b). No complications were recorded in six of seven studies with a total of 204 patients; one study did not mention any complications. All studies reported a significant reduction of pain after treatment of painful scars: only in two of these studies was there no difference found in one (Rigotti et al., 2007) and in two (Huang et al., 2015a) patients out of the entire population. Three studies included control groups, where lipofilling was compared with no treatment (Caviggioli et al., 2011; Maione et al., 2014b; Panettiere et al., 2009). Two of these studies, performed at the same institute, focused on lipofilling as treatment for neuropathic pain after total mastectomy (Caviggioli et al., 2011) or breast-conserving surgery (Maione et al., 2014b). In both studies, it was shown that lipofilling can reduce pain as measured on a visual analogue scale by approximately 3 points in the lipofilling group, compared with about 1 point in the control group. The third study compared results with a representative patient cohort: women who have undergone breast reconstruction and irradiation after mastectomy (Panettiere et al., 2009). In the lipofilling group there was a significant improvement of all parameters of the LENT-SOMA classification (pain, telangiectasias, breast oedema, atrophy and fibrosis) after treatment. For unknown reasons, the authors did not compare and analyse the treatment group with a control group, but they still concluded that lipofilling leads to pain relief as well as amelioration of scar appearance.

3.2. Influence of lipofilling in scars at the tissue level

Microscopically, scars display a loss of rete ridges, sebaceous glands and hair follicles. Also, they are characterized by increased dermal and epidermal thickness (Beausang et al., 1998; Ehrlich et al., 1994). The epidermal thickening is caused by excessive proliferation of keratinocytes. In the dermis, the thickening is caused by excessive extracellular matrix (ECM) production by myofibroblasts, mainly consisting of collagen type I (van der Veer et al., 2009). Not only is there an increase in the amount of collagens, but also in the collagen fibre thickness, maturation and degree of disorganization (Beausang et al., 1998; Ehrlich et al., 1994). Even though there is an increase in the amount of ECM in scarring, some components of normal skin (e.g. elastin, decorin) are less abundant in scars (Niessen et al., 1999).

In two patient studies, skin biopsies have been acquired before and after treatment of scars with lipofilling (Bruno et al., 2013; Klinger et al., 2008), one study evaluating a complete series of biopsies from a single patient (Klinger et al., 2008). After lipofilling, the general structure of the skin improved, collagen was remodelled and there was an increase in vascularization.

In a large, placebo-controlled study, lipofilling in large burn scars was compared with saline injection (Bruno et al., 2013). In 96 patients, half of the scar was injected with saline (placebo- or sham-treated group), the other half was injected with lipoaspirate. Skin biopsies were taken and analysed after 3 and 6 months. Overall, the histological structure of the scars returned near to that of normal skin: a better organization and alignment of collagen fibrils, better vascularization of the dermal papillae, less melanocytic activity in the epidermis and an increase of the amount of elastin fibres. On cellular level, there was an increase in cell divisions in the basal layer of the epidermis and Langerhans cells migrated downwards into this basal layer. Also, levels of pro-fibrotic factor transforming growth factor beta 1 (TGF-β1) and pro-angiogenic factors vascular endothelial growth factor (VEGF) decreased.

In summary, histological improvement in scar appearance was noted in both studies, expressed as a plethora of changes on both histological as well as cellular level. However, why and how lipofilling results in the improvement of all these aforementioned aspects of scarring, including pain reduction, remains to be elucidated.

3.3. Animal studies

In contrast to clinical studies thus far, experimental animal models have been able to demonstrate the mechanisms and influence of lipofilling on dermal scars, scar exterior and scar pain (Table 2a).

Scar histology has been investigated in two studies using irradiation skin damage models in rodents (Garza et al., 2014; Sultan et al., 2011; Table 2a). Skin fibrosis after radiation in general is a clinically relevant problem, which can easily be reproduced in rodents. After radiation, dermatitis develops, which eventually gives rise to fibrotic skin characterized by epidermal thickening and irregular deposition of collagen in the dermis. Also, compared with normal skin, irradiated skin areas have an increased vessel density. In two studies in mice, it has been shown that treatment with lipofilling can reduce all these hallmark features of radiation-damaged skin (Garza et al., 2014; Sultan et al., 2011). A decrease in SMAD3 protein levels, a key protein in the pro-fibrotic pathway TGF-β/Smad signal transduction pathway, partly explains the mechanism of scar improvement (Sultan et al., 2011). In a slightly different model in mice with full thickness burn wounds, it has been shown that lipofilling leads to better scar appearance by increasing pro-angiogenic factors VEGF and stromal cell-derived factor 1 (SDF-1) and decreasing pro-fibrotic factor TGF-β1 (Sultan et al., 2012).

Reduction of neuropathic pain has been reported in two studies of Huang and co-workers (Huang et al., 2014, 2015b; Table 2b). Alloodynia, painful perception of a normally non-painful stimulus, after burn wound injury

© 2017 The Authors Journal of Tissue Engineering and Regenerative Medicine Published by John Wiley & Sons Ltd J Tissue Eng Regen Med 2017; 11: 3220–3235. DOI: 10.1002/term
### Table 1b. Clinical studies on lipofilling to reduce pain

<table>
<thead>
<tr>
<th>Reference</th>
<th>Study type</th>
<th>Study population</th>
<th>Intervention</th>
<th>Follow-up</th>
<th>Results</th>
<th>Complications</th>
</tr>
</thead>
<tbody>
<tr>
<td>Caviggioli et al. (2011)</td>
<td>Retrospective, controlled</td>
<td>Patients with severe scar retraction and PMPS after mastectomy with axillary dissection and radiotherapy (n = 113).</td>
<td>Intervention: dermal-hypodermal junction lipofilling (n = 72). Control: no lipofilling treatment (n = 41).</td>
<td>Pain evaluation using a VAS (mean follow-up of 13 months).</td>
<td>Decrease of pain in treated group compared with untreated group.**</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Huang et al. (2015a)</td>
<td>Prospective, non-controlled, non-blinded, non-randomized</td>
<td>Patients with painful neuroapthic scars with persistent symptoms (n = 13); (range 3 months–13 months).</td>
<td>Intervention: dermal-hypodermal junction lipofilling. Control: saline injection.</td>
<td>Pain evaluation using VAS and NPSI scores (pre-operative, 1 week, 4 weeks and 24 weeks post-operative).</td>
<td>Decrease of VAS and VSS scores after 1, 4 and 24 weeks compared with pre-operative scores. ** No other comparisons between post-operative measurements performed. No effect in 2 cases.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Klinger et al. (2013)</td>
<td>Retrospective, semi-controlled non-blinded, non-randomized</td>
<td>Patients with retractive and painful scars compromising daily activity (n = 20). Scar age of &gt; 2 years.</td>
<td>Intervention: dermal-hypodermal junction lipofilling. Control: saline injection.</td>
<td>Pain and skin quality of the scar was evaluated using the POSAS questionnaire (without control group). Scar hardness was measured using the durometer (with control group). Both after 3 months.</td>
<td>No significance difference ((P &gt; 0.05)).</td>
<td>No complications mentioned</td>
</tr>
<tr>
<td>Malone et al. (2014b)</td>
<td>Prospective, controlled, non-blinded, non-randomized</td>
<td>Patients with PMPS after lumpectomy and radiotherapy (n = 90). Lipofilling performed &gt; 1 year after radiotherapy.</td>
<td>Intervention: dermal-hypodermal junction lipofilling (n = 59). Control: no lipofilling treatment (n = 41).</td>
<td>Evaluation of spontaneous pain using a VAS (pre-operative and 1 year post-operative).</td>
<td>A mean decrease of pain of 3.1 in the treated group and 0.9 in the control group. More decrease of pain in the treated group compared with the control group. ** Scores for pain, telangiectasia, breast oedema, atrophy and fibrosis decreased in the intervention group after 3 months. ** No significance difference for above mentioned scores compared with the control group after 3 months. Aesthetic outcome improved in the intervention group compared with the control group.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Panettiere et al. (2009)</td>
<td>Prospective, controlled, non-blinded, non-randomized</td>
<td>Patients with irradiated reconstructed breasts after mastectomy for carcinomas (n = 61, 62) breasts.</td>
<td>Intervention: subscar lipofilling (serial interventions until patient was satisfied or result was stable (n = 20). Control: no lipofilling treatment (n = 41).</td>
<td>Functional results were evaluated using the LENT-SOMA scoring system, 3 months after the last treatment. Aesthetic results were evaluated using a 5-grade scale.</td>
<td>No significant complications reported</td>
<td></td>
</tr>
<tr>
<td>Rigotti et al. (2007)</td>
<td>Prospective, non-controlled, non-blinded, non-randomized</td>
<td>Patients with side-effects of radiotherapy with severe symptoms and irreversible function damage (LENT-SOMA scale grade 3 and 4; (n = 20). Scar age 1–30 years.</td>
<td>Intervention: purified lipofilling.</td>
<td>LENT-SOMA grading scale scores evaluation (mean follow-up of 30 months).</td>
<td>Reduction of LENT-SOMA grading scale scores. ** Improvement observed in all patients, except 1 case.</td>
<td>No complications reported</td>
</tr>
<tr>
<td>Ulich et al. (2012)</td>
<td>Prospective, non-controlled, non-blinded, non-randomized</td>
<td>Patients with painful episiotomy scars (n = 20). Mean time after episiotomy was 10.3 months.</td>
<td>Intervention: subscar lipofilling.</td>
<td>Perineal pain evaluation using a MGPQ, a PPI and VAS. The SSSRS was used to evaluate the sexual satisfaction of the patients (pre-operative, 1, 3 and 6 months).</td>
<td>Reduction of pain after 1, 3 and 6 months in all pain questionnaires. ** Improvement in sexual satisfaction after 1, 3 and 6 months. No comparison performed between post-operative time points.</td>
<td>No major complications reported</td>
</tr>
</tbody>
</table>

**Abbreviations:** VSS = Vancouver scar scale, TAM = total active movement, GSM = grip strength measurement, DASH = disabilities of the arm, shoulder and hand, MHQ = Michigan hand outcome questionnaire, POSAS = patient and observer scar assessment scale, MRS = magnetic resonance scan, MRM = modified radical mastectomy, IIBR = immediate implant-based reconstruction, PMRT = post-mastectomy radiotherapy, PMPS = post-mastectomy pain syndrome, VAS = visual analogue scale, NPSI = neuropathic pain symptom inventory, MGPQ = McGill pain questionnaire, PPI = present pain intensity index, SSSRS = Saltzberg sexual self-rating scale.

*Significant difference \((P < 0.05)\).*

**Significant difference \((P < 0.001)\).*
was tested in rats by means of behavioural testing. After burn injury, lipofilling reduced burn-induced allodynia. On the one hand, lipofilling reduces skin fibrosis and scarring after burn injury (Huang et al., 2014, 2015b) and lowers expression of pro-inflammatory mediators in the skin (Huang et al., 2015b). On the other hand, lipofilling induces changes in the spinal cord as well decreases microglial activation and lessens activation of the pro-inflammatory NFKB signal transduction pathway in spinal cord cells (Huang et al., 2015b).

It can be concluded that lipofilling in rodent models for skin injury and fibrosis reduces adverse fibrotic changes. This appears to be mediated by factors from the lipograft that can inhibit activation of both fibrotic and inflammatory signal transduction pathways. All changes caused by lipofilling in a dermal scar have been drawn schematically in Figure 1.

4. Therapeutic mode of action of ADSC

4.1. ADSC: stem or stromal cells?

Because of their ability to differentiate into different cell types, ADSC are sometimes referred to as adipose stem cells. However, a true stem cell has the potential to differentiate into other cell types, while maintaining a stable population of stem cells by the process of self-renewal (Vogel et al., 1968) with indefinite proliferation capability due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995). Embryonic stem cells are an example of such pluripotent stem cells: due to telomerase activity (Lansdorp, 1995).

Table 2a. Animal studies on lipofilling to improve scar appearance

<table>
<thead>
<tr>
<th>Reference</th>
<th>Animal model</th>
<th>Intervention</th>
<th>Follow up</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Garza et al. (2014)</td>
<td>Mouse</td>
<td>Radiation of scalp skin</td>
<td>Treatment: lipofilling (human adipose tissue) 4 weeks after irradiation. Control: no lipofilling and/or no irradiation.</td>
<td>Histology of skin for epidermal thickness (H&amp;E), collagen arrangement (picrosirius red) and vessel density (CD31). CF for fat graft retention. Histology of fat graft. Assessments 2 and/or 8 weeks after lipofilling.</td>
</tr>
<tr>
<td>Sultan et al. (2011)</td>
<td>Mouse</td>
<td>Full thickness burn wound on dorsum</td>
<td>Treatment: lipofilling (human adipose tissue) 2 weeks after irradiation. Control: saline injection</td>
<td>Blood flow measurement by Laser-Doppler. Photographs. Histology for collagen arrangement (picrosirius red) and vessel density (CD31). Gene and protein expression analysis of skin. Assessment 4 and/or 8 weeks after lipofilling.</td>
</tr>
<tr>
<td>Sultan et al. (2011)</td>
<td>Mouse</td>
<td>Radiation of dorsum skin</td>
<td>Treatment: lipofilling (human adipose tissue) 4 weeks after irradiation. Control: saline injection and/or no irradiation</td>
<td>Photographs. Histology for epidermal thickness (H&amp;E), collagen arrangement (picrosirius red), vessel density (CD31) and pro-fibrotic marker (Smad3). All at 4 and/or 8 weeks after lipofilling.</td>
</tr>
</tbody>
</table>

Abbreviations: H&E = haematoxilin and eosin, MTC = Masson’s trichrome, IL-1β = interleukin 1 beta, COX-2 = cyclo-oxygenase 2, TNFα = tumour necrosis factor alpha, CD31 = cluster of differentiation 31, INOS = inducible nitric oxide synthase, nNOS = neuronal nitric oxide synthase.

Table 2b. Animal studies on lipofilling to reduce pain

<table>
<thead>
<tr>
<th>Reference</th>
<th>Animal model</th>
<th>Intervention</th>
<th>Follow up</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huang et al. (2014)</td>
<td>Rat</td>
<td>Full thickness burn wound of hind paw</td>
<td>Treatment: lipofilling (rat adipose tissue) 4 weeks after injury. Controls: saline injection or no treatment, and/or sham burn wound.</td>
<td>Behavioural testing for neuropathic pain: paw withdrawal test with mechanical and heat stimuli. Histology of hind paw skin (H&amp;E, MTC) and of spinal cord (microglial activation). All at 4 weeks after lipofilling.</td>
</tr>
<tr>
<td>Huang et al. (2015b)</td>
<td>Rat</td>
<td>Full thickness burn wound of hind paw</td>
<td>Treatment: lipofilling (rat adipose tissue) 4 weeks after injury. Controls: saline injection and/or sham burn wound</td>
<td>Behavioural testing for neuropathic pain: paw withdrawal tests. Assessment of inflammatory markers in hind paw skin (COX-2, INOS, nNOS) and spinal cord (IL-1β, TNFα, p-IRB and p-NFKB). All at 4 weeks lipofilling.</td>
</tr>
</tbody>
</table>
capacity of proliferation (Mizuno et al., 2012). ADSC can only differentiate into a limited number of cell types, which makes them multipotent progenitor cells. Hence, in the case of ADSC, the authors prefer to speak of adipose-derived stromal cells instead of adipose-derived stem cells.

4.2. Isolation

Adipose-derived stem or stromal cells can be isolated either from intact adipose tissue or from lipoaspirates. The adipose tissue or lipoaspirate is subjected to enzymatic digestion using proteases such as collagenase, dispase or trypsin (Bourin et al., 2013; Pittenger et al., 1999; Yoshimura et al., 2006; Zuk et al., 2001). After digestion, the stromal vascular fraction (SVF) that contains ADSC as well as several other cell types is separated from the mature adipocytes by differential or density gradient centrifugation (Bourin et al., 2013; Pittenger et al., 1999; Yoshimura et al., 2006; Zuk et al., 2001). For cell culture, the SVF is then seeded into cell culture dishes. Only ADSC adhere to the tissue culture plastic, whereas other, non-adherent cell types such as erythrocytes, endothelial cells and immune cells are removed by washing (Bourin et al., 2013). Then, the remaining ADSC are culture-expanded or cryopreserved until further use.
4.3. ADSC in vivo vs. in vitro

Adipose tissue contains two major components: SVF and adipocytes. SVF is a heterogenous mix of cells of 11 main subpopulations based on CD-surface marker expression: seven adipose-derived populations (CD45−) and four blood-derived populations (CD45\textsuperscript{pos}, CD31\textsuperscript{pos}, CD105\textsuperscript{pos}, CD146\textsuperscript{pos}). Three important subpopulations of CD45\textsuperscript{min} cells are pericytes [in vivo: (CD34\textsuperscript{pos}/CD34\textsuperscript{min}/CD146\textsuperscript{pos}/CD31\textsuperscript{min}], supra adventitial cells (in vivo: CD34\textsuperscript{pos}/CD146\textsuperscript{min}/CD31\textsuperscript{min}] and ADSC (in vivo: CD34\textsuperscript{pos}/CD90\textsuperscript{pos}/CD31\textsuperscript{min}/CD105\textsuperscript{low}) in a very low number (Corselli et al., 2012, 2013; Yoshimura et al., 2006; Zimmerlin et al., 2010). Pericytes and supra-adventitial cells are both identified as precursor cells of ADSC, but there remains controversy (Corselli et al., 2012; Lin et al., 2008; Traktuev et al., 2008; Zimmerlin et al., 2010).

Enzymatic isolation and culture of those precursor cells or ADSC results in a large series of cells that can be used in regenerative medicine. After several days of culture, the in vivo phenotype of precursor cells changes into an in vitro specific phenotype. Most of the cells will lose their CD34 expression, and almost all of the cells gain expression of CD105 (Corselli et al., 2012, 2013; Yoshimura et al., 2006; Zimmerlin et al., 2010). The CD105 marker is also known as endoglin and is a TGF-β type III receptor, which is expressed on virtually all cells of mesenchymal origin, but also on for example endothelial cells. Ten–20% of the subpopulations remain CD34\textsuperscript{pos}, but their proliferation rate and adipogenic differentiation ability is significantly lower as compared with the CD34\textsuperscript{min} subpopulation (Yoshimura et al., 2006; Zimmerlin et al., 2010). This suggests that 80–90% of the so-called ADSC, characterized by their phenotype in vitro (CD34\textsuperscript{min}/CD105\textsuperscript{pos}), are not present in vivo: in other words, the majority of ADSC acquire their phenotype through culturing. Culturing of ADSC also causes dramatic shifts in secretome, as will be discussed within a few sentences below. The different components and cell types of all fractions of adipose tissue are summarized in Figure 2.

Some studies have described that regenerative potencies of ADSC are caused by secretion of trophic factors or differentiation into other cells (Yang et al., 2013). In vivo, little is known about the secretion of trophic factors by ADSC. In vitro, secretion of trophic factors by ADSC in medium (called ADSC conditioned medium) is affected by many aspects: differences in culture conditions, donors, methods and medium, and cell counts results in different expression of growth factors. For instance, hypoxia culture upregulates VEGF, platelet-derived growth factor, placental growth factor and insulin-like growth factor II (Pawitan, 2014). A 3D culture structure results in thousands of genes with a significantly higher mRNA expression related to ECM, cell adhesion, wound healing and growth factors as compared with a 2D structure (Amos et al., 2010). Concentrations of proteins related to angiogenesis, ECM remodelling and regeneration increase as well (Amos et al., 2010).

The regenerative potency of SVF might be caused by the interaction between cells and growth factors. For example, angiogenesis is significantly greater when pericytes and endothelial cells are combined rather than the use of pericytes or endothelial cells alone (Traktuev et al., 2009). Growth factors like VEGF, hepatocyte growth factor, TGF-β and ECM stimulate angiogenesis (Rehman et al., 2004). ECM influences morphogenesis, and migration speed depends on ECM density during angiogenesis (Bauer et al., 2009). Furthermore, ECM functions as a scaffold for other cell types at the site of injection. The interaction of cellular integrins, i.e. matrix receptors, suppresses pro-apoptotic signalling. Thus, applications that include intact, non-enzymatic, generated SVF might favour graft survival. However, only mechanical isolation of SVF preserves ECM, while enzymatic isolation of SVF disrupts all communicative connections between cells. As compared with cultured ADSC and in vitro studied growth factors, freshly isolated SVF contain cells with their in vivo phenotype and growth factor secretion, respectively. As compared with lipofilling, the use of SVF might avoid possible complications like cyst formation or overfilling (Agostini et al., 2014), because only small volumes (less than 10 ml) of SVF are injected. Thus, because injected volume is limited, there is no risk of overfilling. Because no adipocytes are injected, there is also no risk of oily cyst formation.

5. ADSC as an anti-scarring treatment

5.1. Clinical studies

To date, the use of ADSC as a cell therapy for treatment for fibrosis has not been thoroughly investigated in clinical studies. ADSC have been applied in two non-controlled, non-randomized studies investigating the effect of ADSC-enriched lipografts on healing of chronic, intractable radiation ulcers in 10 patients (Akita et al., 2012) and for correction of soft tissue defects in 29 patients (Tiryaki et al., 2011). It was concluded that ADSC improve wound healing (Akita et al., 2012) and fat graft take (Tiryaki et al., 2011), and concomitantly decrease deep tissue fibrosis and dermal scarring. However, fundamentally, there is ample evidence for these effects: ADSC increase angiogenesis, can induce mitosis in resident tissue cells and are able to remodel ECM. Based on the design of both studies, no definitive conclusions can be drawn on the effectiveness of the use of ADSC as scar treatment.

On the other hand, studies in the field of cell-assisted lipotransfer (CAL), where lipografts are combined with ADSC in order to improve fat graft survival, have been several properly designed, controlled clinical trials (Kolle et al., 2013; Peltoniemi et al., 2013; Tanikawa et al., 2013) to demonstrate the efficacy of CAL for improvement of lipograft survival over lipofilling alone. In these studies no serious adverse events were reported after injection of autologous freshly isolated (Peltoniemi et al., 2013; Tanikawa et al., 2013) or culture expanded (Kolle et al., 2013) ADSC. It can be concluded that use of autologous ADSC in patients is safe. These clinical trials warrant the dissection of the
underlying mechanism via animal models and in vitro investigations of underlying molecular pathways.

5.2. Animal studies

In animal wound-healing models, where ADSC were used to speed up wound healing (Lam et al., 2013; Lee et al., 2011; Uysal et al., 2014; Zonari et al., 2015), it was observed that ADSC reduce severity of scarring after wound closure (Table 5). ADSC improved the wound healing rate in three out of four studies, and smaller fibrotic areas remained after wound healing (Lam et al., 2013). Yet, the epidermal thickness increased (Uysal et al., 2014; Zonari et al., 2015), and the gene expression of the pro-fibrotic markers α-smooth muscle actin and TGF-β1
Adipose tissue and ADSC for fibrotic scar treatment

Table 5. Animal studies on ADSC as a treatment for wound healing and scar prevention or reduction

<table>
<thead>
<tr>
<th>Reference</th>
<th>Animal model</th>
<th>Biomaterial</th>
<th>Intervention</th>
<th>Follow up</th>
<th>Results</th>
</tr>
</thead>
<tbody>
<tr>
<td>Castiglione et al. (2013)</td>
<td>Rat</td>
<td>No</td>
<td>1 × 10^5 labelled human ADSC in scaffold: PBS Control: PB Local injection</td>
<td>Protein expression and histomorphometric analysis of the penis. Ectine function measurements 5 weeks after ADSC treatment.</td>
<td>Decrease in collagen III and elastin deposition (immunofluorescence). Improved erectile function. Both in ADSC-treated vs. control group.</td>
</tr>
<tr>
<td>Lam et al. (2013)</td>
<td>MouseSplinted excisional wound healing model</td>
<td>Small intestinal submucosa (SIS)</td>
<td>1 × 10^5 mouse ADSC on SIS patch Control: patch alone or Topical application of ADSC</td>
<td>Wound healing speed, fibrosis (H&amp;E and MTC staining) after wound healing. Measured at day 14 after wounding.</td>
<td>Wound healing improved slightly with ADSC on SIS. Decreased fibrotic area with topical ADSC and with ADSC on SIS Both compared ADSC on SIS with untreated or SIS alone.</td>
</tr>
<tr>
<td>Lee et al. (2011)</td>
<td>Nude mouseSplinted excisional wound healing model</td>
<td>Collagen gel</td>
<td>1 × 10^5 human ADSC in collagen gel Control: human dermal fibroblast in collagen gel or, collagen gel alone</td>
<td>Photographs of wound area size 10 days after wounding. Scar size 28 days after wounding (H&amp;E staining).</td>
<td>Slightly decreased scar size in ADSC and DF collagen gel groups compared with control (based on H&amp;E staining alone). Increased wound healing speed, neovascularization and epithelial thickness. Lower sTGF-β1, αSMA and j2 and j3 and higher FGF and VEGF expression. All outcomes for ADSC and BMSC treated groups vs. control group</td>
</tr>
<tr>
<td>Uysal et al. (2014)</td>
<td>RatFull thickness</td>
<td>No</td>
<td>1 × 10^5 labelled rat ADSC in scaffold: PBS Control: PBS Local injection</td>
<td>Wound healing speed. Histology for neovascularization, epithelial thickness (both H&amp;E). Immunostaining for cytokeratin, αSMA, FGF, VEGF, TGF-β1, j2 and j3. All at day 56 after wounding.</td>
<td>Slightly lower scar area and slightly higher pliability. Higher amount of mature collagen. Lower mast cell count. Lower gene expression of sSMA and TGF-β1, higher expression of MMP1. All outcomes for ADSC treated group vs. control group</td>
</tr>
<tr>
<td>Yun et al. (2012)</td>
<td>PigScarring model, after full thickness wound</td>
<td>No</td>
<td>1 × 10^5 labelled human ADSC in scaffold: PBS Control: PBS Three consecutive local injections</td>
<td>Area, colour and flexibility of scar. Histological assessment of collagen arrangement (MTC), number of mast cells. Gene expression analysis of scar tissue. All until 50 days after ADSC injection.</td>
<td>Slightly decreased scar area and slightly higher pliability. Higher amount of mature collagen. Lower mast cell count. Lower gene expression of sSMA and TGF-β1, higher expression of MMP1. All outcomes for ADSC treated group vs. control group</td>
</tr>
<tr>
<td>Zhang et al. (2015)</td>
<td>RabbitHypertrophic scar model, after full thickness wound</td>
<td>No</td>
<td>4 × 10^5 labelled rabbit ADSC in scaffold: ADSC CM, culture medium, or untreated. Local injection</td>
<td>Histology for scar size and collagen arrangement (H&amp;E and MTC). Gene expression analysis of scar tissue. All until 35 days after ADSC injection.</td>
<td>Slightly lower scar area. Lower deposition and better alignment of collagen. Lower gene expression of sSMA and collagen I. All outcomes for ADSC or ADSC CM treated groups vs. culture medium or untreated groups.</td>
</tr>
<tr>
<td>Zonari et al. (2015)</td>
<td>RatFull exisional wound</td>
<td>PHBV scaffold</td>
<td>1 × 10^5 labelled rat ADSC in PHBV scaffold: Control: PHBV scaffold or untreated</td>
<td>Wound healing speed, skin thickness (H&amp;E), vessel density, collagen arrangement (MTC) and gene expression analysis. All until 28 days after wounding.</td>
<td>No difference in wound-healing speed. Improved skin thickness and collagen fibre organisation. Lower sSMA and TGF-β1, higher TGF-β3 gene expression. No difference in vessel density at 28 days. All these outcomes for ADSC in scaffold vs. scaffold alone.</td>
</tr>
</tbody>
</table>

**Abbreviations:** ADSC = adipose-derived stem/stromal cell, SIS = small intestinal submucosa, H&E = haematoxylin and eosin, MTC = Masson trichrome, DF = dermal fibroblast, sSMA = alpha smooth muscle actin, FGF = fibroblast growth factor, VEGF = vascular endothelial growth factor, TGF-β = transforming growth factor beta, BMSC = bone marrow mesenchymal stem/stromal cell, PBS = phosphate-buffered saline, TIMP1 = tissue inhibitor of metalloproteinase, MMP = matrix metalloproteinase, ADSC CM = ADSC conditioned medium, PHBV = polyhydroxybutyrate-co-hydroxyvalerate.

decreased (Uysal et al., 2014; Zonari et al., 2015) while the gene expression of anti-fibrotic fibroblast growth factor and pro-angiogenic VEGF (Uysal et al., 2014) increased. Together, this indicates that in vivo administered ADSC suppress the formation of dermal scar, through augmented wound healing. The comparison with clinical treatment of pre-existing scars is hampered, because these animal studies more prevent scar formation than revert pre-existing scars.

In animal models specifically designed to study scarring (Yun et al., 2012; Zhang et al., 2015) and to study the fibrotic disorder of Peyronie’s disease (Castiglione et al., 2013; Table 5), it was noted that deposition of ECM components, such as collagen type I and III and elastin, was decreased after treatment of scars with ADSC. Also, collagen fibre alignment improved in the treated scar areas (Yun et al., 2012; Zhang et al., 2015). Functionally, treatment of scars with ADSC leads to smaller scars (Yun et al., 2012) and less scar elevation (Yun et al., 2012). Together, we surmise that the remodelling of the fibrotic matrix in a scar by ADSC is one of the components that governs scar reduction. Interestingly, ADSC are derived from connective tissue (SVF of fat), but appear to act as ‘good guys’ in contrast to the scar myofibroblasts, which are connective tissue cells too, but ‘bad guys’. The ADSC are capable of tilting the balance between ECM deposition and ECM degradation in favour of degradation. Whether this depends solely on matrix influence or also on direct influence on the scar-resident myofibroblast remains to be investigated.

In conclusion, treatment of wounds or mature scars with ADSC in different animal models has shown to result in faster wound healing and reduction of scar tissue on both macroscopic and microscopic levels. Thus, the use of autologous ADSC to improve wound healing and to prevent or diminish scar tissue in patients seems to be a very exciting and promising way to go.
Figure 3. Harnessing the power of fat for fibrotic scar treatment: as whole adipose tissue in lipoinjection, or in loose components such as stromal vascular fraction (SVF), adipose-derived stem or stromal cells (ADSC) or ADSC conditioned medium. As listed, we propose each form has its own ideal application. [Colour figure can be viewed at wileyonlinelibrary.com]
5.3. In vitro studies

Myofibroblasts play a major role in wound healing and scarring: activated myofibroblasts proliferate, produce ECM-like collagens and have the ability to contract. After wound healing, myofibroblasts normally are resolved via apoptosis. However, if myofibroblasts persist, scarring will be the end result (Klingberg et al., 2013). In two in vitro studies, it has been shown that trophic factors, produced by ADSC, can inhibit the myofibroblast phenotype of dermal fibroblasts after stimulation with the pro-fibrotic cytokine TGF-β1 (Spiekman et al., 2014) and can inhibit that of fibroblasts derived from Dupuytren’s nodules (Verhoekx et al., 2013). Proliferation, ECM production and contraction of these fibroblasts were reduced, which indicates that growth factors and cytokines of ADSC have the ability to prevent or even to reverse dermal scarring.

6. Future perspectives

As discussed throughout, harnessing the power of fat for fibrotic scar treatment is an emerging concept in regenerative medicine. Fat can, however, be used in several fashions: as whole adipose tissue in lipofilling, or in loose components such as SVF, ADSC or even ADSC conditioned medium. In our opinion, each of these forms has its own ideal application in regenerative medicine (Figure 3). The use of whole adipose tissue in lipofilling is optimal when there is a soft tissue defect that needs filling. Besides the ‘volumizing’ effect, scar reduction is a beneficial side-effect of this treatment. Though, when extra volume is not a requirement or even a contraindication, the use of SVF offers an excellent alternative. In the setting of fibrotic dermal scars in areas where addition of extra volume is not aesthetically desirable, SVF is a good alternative for whole adipose tissue. Besides for use in dermal fibrotic scars, use of SVF opens the door for other clinical applications. Whole adipose tissue is not fit for use in fibrotic disorders in organs, such as cardiac or liver fibrosis. SVF, however, would be a suitable alternative to combat organ fibrosis. SVF has all the requirements to act as a scaffold for repair, as it contains ready-to-use microvasculature, ECM and ADSC to orchestrate the repair process. For example, acceleration of wound healing or alteration of early scar formation would be exemplary candidates for use of SVF. Nonetheless, in case of pre-existing scars, a more rigorous remodelling of the mature scar tissue is necessary. Here, the microvasculature and ECM components of SVF are not a prerequisite. Thus, the application of ADSC would suffice. ADSC could orchestrate the remodelling, for example by immunomodulation or by instruction of the resident tissue cells from a synthetic to a proteolytic or a non-contractile phenotype. Last but not least, ADSC conditioned medium offers the ultimate solution when only instructive (growth) factors are required. In this way, use of allogeneic cells or xenogenic cell culture products can be circumvented, resulting in an off-the-shelf product. ADSC conditioned medium would be ideal for topical application or injection in wounds or developing scars.

7. Conclusion

Since Neuber’s first report in 1893, the use of adipose tissue has gradually developed into an exciting new way to be used in the treatment and prevention of scar tissue. After lipofilling or after application of ADSC, improvement of scar appearance or reduction in scar-related pain has been reported in many case reports and clinical studies. Lipofilling and ADSC seem promising to lessen the severity of developing as well as pre-existent fibrotic scarring. A factor that complicates definitive conclusions in the efficacy of lipofilling and ADSC is the wide variety in experimental design of the studies. Each study uses different outcome measurements, at different time points in pre-existent as well as in developing scarring. Up to date, large randomized controlled clinical trials using lipofilling, ADSC, SVF or ADSC conditioned medium for fibrotic scar treatment are still lacking. For future randomized controlled clinical trials, we recommend researchers to carefully select their source of stromal cells depending on their goal.

Conflict of interest

The authors have no conflicts of interest to disclose in relation to the content of this work.

References


Lansdorp PM. 1995; Telomere length and proliferation under ischemia: death of adipocytes and activation of perivascular mesenchymal stromal/stem cells. Stem Cells Dev 21(13): 2245–2252.


